Overview

Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis

Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
To prevent portal vein thrombosis (PVT) in patients with cirrhosis at risk for PVT by pharmacologic prophylaxis with intravenous antithrombin (AT-III).
Phase:
Phase 1
Details
Lead Sponsor:
Jonathan Stine
Collaborator:
Grifols Therapeutics LLC
Treatments:
Antithrombin III
Antithrombins